Compare Abbott Laboratories (ABT) vs Workiva Inc (WK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Workiva Inc — how do they compare? Abbott Laboratories trades at $95.48 (market cap $166.94B), while Workiva Inc trades at $52.65 (market cap $2.97B). The key difference: Abbott Laboratories is far larger — about 56.2× Workiva Inc's market cap, and Abbott Laboratories pays a 2.63% dividend while Workiva Inc pays none. Which is the better fit depends on your goals.
| ABT | WK | |
|---|---|---|
Market Cap | $166.94B | $2.97B |
Sector | Health | Technology |
52-Week High | $136.62 | $93.31 |
52-Week Low | $82.57 | $44.31 |
Enterprise Value | $193.69B | $2.90B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Workiva (WK) trades at $51.54, down 0.75% on the day, with a bullish technical signal from moving averages and strong analyst consensus. The company reported Q1 2026 EPS of $0.77, beating estimates, and shows improving revenue trends. Cash flow from operations grew to $140.07M in 2025, with net income turning positive in 2026 projections. Recent news highlights AI adoption in finance and upcoming Q2 2026 earnings.
Outlook remains positive with a consensus price target of $71.00, implying 38% upside, supported by 16 buy ratings. Risks include high valuation multiples (P/E 214.75) and reliance on sustained earnings growth. The stock presents a growth opportunity if execution continues, but volatility near resistance at $52 warrants monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Workiva Inc
Workiva is a leading provider of cloud-based platforms for complex reporting and compliance. It enables organizations to connect and manage data across financial reporting, ESG (Environmental, Social, and Governance), and GRC (Governance, Risk, and Compliance), serving as a single source of truth for auditable, transparent disclosures to regulators and stakeholders.
Read more on WK →
